163 related articles for article (PubMed ID: 34926262)
1. Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report.
Shen Q; Qu J; Chen Z; Zhou J
Front Oncol; 2021; 11():760097. PubMed ID: 34926262
[TBL] [Abstract][Full Text] [Related]
2. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
Liu J; Jin B; Su H; Qu X; Liu Y
BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
[TBL] [Abstract][Full Text] [Related]
3. Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.
Li G; Fang M; Zhou Y; Liu X; Tian P; Mei F
Heliyon; 2023 Oct; 9(10):e20690. PubMed ID: 37860534
[TBL] [Abstract][Full Text] [Related]
4.
Ma L; Chen R; Wang F; Ma LL; Yuan MM; Chen RR; Liu J
Ann Transl Med; 2019 May; 7(9):207. PubMed ID: 31205925
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Patients with
Sanchis-Borja M; Guisier F; Swalduz A; Curcio H; Basse V; Maritaz C; Chouaid C; Auliac JB
Onco Targets Ther; 2024; 17():439-448. PubMed ID: 38836187
[TBL] [Abstract][Full Text] [Related]
6. Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q.
Song Y; Jia Z; Wang Y; Wang Y; Liu P; Zhang S; Bing Z; Cao L; Cao Z; Rossi E; Zamarchi R; Denis MG; Camps C; Fernandez-Diaz AB; Liang N; Li S
J Thorac Dis; 2020 May; 12(5):2771-2780. PubMed ID: 32642185
[TBL] [Abstract][Full Text] [Related]
7. L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment.
Li M; Qin J; Xie F; Gong L; Han N; Lu H
Discov Oncol; 2022 Aug; 13(1):72. PubMed ID: 35943592
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment.
Li HS; Yang GJ; Wang Y
Front Oncol; 2021; 11():649843. PubMed ID: 33937055
[TBL] [Abstract][Full Text] [Related]
9. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
Walia M; Singhal MK; Kamle MS
Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
[TBL] [Abstract][Full Text] [Related]
10. Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib.
Wang Y; Han R; Zhu M; He T; He Y
Front Oncol; 2022; 12():875313. PubMed ID: 35530305
[TBL] [Abstract][Full Text] [Related]
11. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation.
Shen G; Shi L; Tian X; Huang D; Chen H; Gao C; Shen X; Zhang H
Front Pharmacol; 2021; 12():731895. PubMed ID: 34987382
[TBL] [Abstract][Full Text] [Related]
13. Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports.
Zeng Y; Feng Y; Fu G; Jiang J; Liu X; Pan Y; Hu C; Liu X; Wu F
Front Pharmacol; 2022; 13():838247. PubMed ID: 35462930
[TBL] [Abstract][Full Text] [Related]
14. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
16. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
Wu L; Zhong W; Li A; Qiu Z; Xie R; Shi H; Lu S
Ann Transl Med; 2021 Jun; 9(11):950. PubMed ID: 34350265
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells.
Katayama Y; Yamada T; Tokuda S; Okura N; Nishioka N; Morimoto K; Tanimura K; Morimoto Y; Iwasaku M; Horinaka M; Sakai T; Kita K; Yano S; Takayama K
Cancer Med; 2022 Feb; 11(4):944-955. PubMed ID: 35029047
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of afatinib in an NSCLC patient with
Nozaki K; Watanabe S; Nishio K; Sakai K; Kikuchi T
Transl Cancer Res; 2022 Jan; 11(1):295-298. PubMed ID: 35261905
[TBL] [Abstract][Full Text] [Related]
20. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
